News | April 05, 2026
Senores makes bold US push with new federal-focused JV
Company leadership is framing the move as transformational.
Company leadership is framing the move as transformational.
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Subscribe To Our Newsletter & Stay Updated
